Ardent Health vs Encompass Health
ARDT and EHC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDT and EHC compare
Encompass Health is the larger company, worth 7.6 times as much as Ardent Health ($13.0B against $1.7B).
On earnings, Encompass Health is cheaper: it trades at 21.4× trailing earnings, against 21.9× for Ardent Health.
Encompass Health grew revenue faster over the last twelve months (9.5% versus 3.3% for Ardent Health).
Encompass Health keeps more of each dollar of sales as profit, with a net margin of 10.0% compared with 1.2% at Ardent Health.
Encompass Health pays a dividend yielding 0.59%; Ardent Health does not pay one.
Encompass Health scores higher on the StockData Score (17 against 8 for Ardent Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDT | EHC |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $13.0B |
| Share price | $12.03 | $131.49 |
| Change, 1 year | −19.9% | 4.1% |
| Change, 5 years | – | 102% |
| Beta (5Y) | 0.56 | 0.70 |
| Employees | 25K | 42K |
| StockData Score | ||
| Total score | 8 | 17 (better) |
| Valuation score | 4 (better) | 2 |
| Growth score | 0 | 4 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 21.9× | 21.4× (better) |
| P/S | 0.3× (better) | 2.1× |
| P/B | 1.3× (better) | 5.0× |
| EV/EBITDA | 6.6× (better) | 10.9× |
| P/FCF | – | 31.4× |
| PEG | – | 0.79 |
| FCF yield | – | 3.2% |
| Fair value | $18.80 | $123.38 |
| Margin of safety | 36.0% (better) | −6.6% |
| Growth | ||
| Revenue growth (TTM) | 3.3% | 9.5% (better) |
| Revenue growth, 5Y average | – | 10.7% |
| Net income growth (TTM) | −69.3% | 18.8% (better) |
| EPS growth (TTM) | −69.6% | 20.2% (better) |
| EPS growth, 5Y average | – | 14.2% |
| Profitability | ||
| Net margin | 1.2% | 10.0% (better) |
| FCF margin | – | 6.7% |
| Return on equity | 6.0% | 25.5% (better) |
| Financial health | ||
| Debt / equity | 0.82 (better) | 1.01 |
| Net debt / EBITDA | 1.01 (better) | 1.68 |
| Current ratio | 2.10 (better) | 1.19 |
| Altman Z-score | 1.89 | 2.81 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.59% |
| Payout ratio | – | 12.1% |
| Years of dividend growth | – | 2 |
| Dividend growth, 5Y average | – | −8.5% |
| Buyback yield | – | 1.9% |
| Shareholder yield | 0.00% | 2.5% (better) |
| Ownership | ||
| Held by institutions | 76.9% | 97.0% |
| Held by insiders | 78.9% | 1.0% |
| Insider net buying, 12 months | $186K (better) | −$47.8M |
| Short interest, % of float | 15.6% | 3.6% |
Go deeper
- ARDT stock overview
- ARDT income statement
- ARDT valuation and score
- EHC stock overview
- EHC income statement
- EHC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.